Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,606,800.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00. Following the completion of the transaction, the director now directly owns 2,071,931 shares of the company’s stock, valued at $221,945,248.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Trading Down 1.7 %

Shares of MRNA opened at $105.14 on Friday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $163.24. The company has a market capitalization of $40.26 billion, a P/E ratio of -8.47 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The firm’s 50 day simple moving average is $99.86 and its 200 day simple moving average is $93.57.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter last year, the company posted $3.61 EPS. The business’s quarterly revenue was down 44.9% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRNA has been the topic of several research reports. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Finally, HSBC reissued a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $126.49.

Institutional Investors Weigh In On Moderna

A number of large investors have recently added to or reduced their stakes in MRNA. Ballentine Partners LLC boosted its holdings in shares of Moderna by 125.4% in the 1st quarter. Ballentine Partners LLC now owns 4,747 shares of the company’s stock worth $506,000 after purchasing an additional 2,641 shares in the last quarter. Douglas Lane & Associates LLC lifted its position in Moderna by 16.9% in the 1st quarter. Douglas Lane & Associates LLC now owns 393,039 shares of the company’s stock worth $41,882,000 after buying an additional 56,901 shares during the last quarter. Sanders Morris Harris LLC purchased a new stake in Moderna in the first quarter worth approximately $285,000. Gulf International Bank UK Ltd grew its position in Moderna by 0.9% during the first quarter. Gulf International Bank UK Ltd now owns 26,814 shares of the company’s stock valued at $2,857,000 after acquiring an additional 228 shares during the last quarter. Finally, Optimum Investment Advisors raised its stake in shares of Moderna by 15.5% during the first quarter. Optimum Investment Advisors now owns 1,489 shares of the company’s stock worth $159,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.